Leuprorelin Suppresses Angiogenesis and Malignant Progression in Endometrial Cancer via Downregulation of the ELAVL1/VEGFA Axis.
Leuprorelin may reduce proliferation and migration of endometrial cancer cells, but its clinical relevance in humans is not established.
Where it sits
this study against the rest of the leuprorelin corpusSummary and findings
Leuprorelin was evaluated for its effects on endometrial cancer (EC) cell lines and in a murine xenograft model. The study measured proliferation, migration, and apoptosis in EC cells, as well as HUVEC tube formation. Results indicated significant reductions in these parameters following leuprorelin treatment.
Abstract
Leuprorelin, a gonadotropin-releasing hormone (GnRH) agonist, is currently used clinically to suppress estrogen-dependent endometrial cancer (EC) through pituitary desensitization. However, whether this agent exerts direct anti-neoplastic effects via post-transcriptional regulatory mechanisms remains unclear. The phenotypic effects of leuprorelin were evaluated in EC cell lines using colony formation, 5-ethynyl-2'-deoxyuridine (EdU) incorporation, Transwell migration, wound healing, flow cytometry, and HUVEC tube formation assays. Mechanistic exploration employed RNA immunoprecipitation (RIP), mRNA decay kinetics analysis, and RNA fluorescence in situ hybridization combined with immunofluorescence microscopy. A murine xenograft model system was implemented for in vivo validation studies. Leuprorelin treatment significantly reduced proliferation and migration of EC cells, induced apoptosis, and suppressed HUVEC tube formation. At the molecular level, leuprorelin administration reduced cytoplasmic accumulation of ELAVL1, an RNA-binding protein that physiologically associates with VEGFA transcripts and enhances their stability. This reduction resulted in accelerated decay of VEGFA mRNA and subsequent downregulation of VEGFA protein expression. Forced overexpression of VEGFA substantially abrogated the anti-tumor effects mediated by leuprorelin. In nude mouse xenograft models, leuprorelin administration suppressed tumor growth and tumor-associated neovascularization, effects that were reversed upon VEGFA overexpression. Leuprorelin impedes EC progression by disrupting ELAVL1-mediated stabilization of VEGFA mRNA, highlighting the ELAVL1/VEGFA axis as a potential therapeutic target for anti-angiogenic therapeutic intervention.
Background
This paper addresses the potential direct anti-neoplastic effects of leuprorelin, a gonadotropin-releasing hormone agonist, on endometrial cancer. Previous knowledge indicates that leuprorelin is used clinically to suppress estrogen-dependent endometrial cancer through pituitary desensitization. Understanding its direct effects on cancer progression could provide insights into new therapeutic strategies.
Methods
The study utilized colony formation, 5-ethynyl-2'-deoxyuridine incorporation, Transwell migration, wound healing, flow cytometry, and HUVEC tube formation assays to evaluate the phenotypic effects of leuprorelin on EC cell lines. A murine xenograft model was employed for in vivo validation. Specific doses and durations were not reported in the abstract.
Results
Leuprorelin treatment significantly reduced proliferation and migration of EC cells, induced apoptosis, and suppressed HUVEC tube formation. The study also found that leuprorelin reduced cytoplasmic accumulation of ELAVL1, leading to accelerated decay of VEGFA mRNA and downregulation of VEGFA protein expression.
Interpretation
The findings suggest that leuprorelin may disrupt the ELAVL1/VEGFA axis, which is implicated in tumor progression. However, the clinical significance of these findings remains uncertain, particularly given the reliance on in vitro and animal models. The small sample size and lack of human data limit the generalizability of the results.
Key findings
- Leuprorelin treatment significantly reduced proliferation and migration of EC cells.
- Leuprorelin induced apoptosis in EC cells.
- Leuprorelin suppressed HUVEC tube formation.
- Forced overexpression of VEGFA substantially abrogated the anti-tumor effects mediated by leuprorelin.
- Leuprorelin administration suppressed tumor growth and tumor-associated neovascularization in nude mouse xenograft models.
Limitations
- In vitro and animal models used, limiting human applicability.
- No specific doses or durations reported in the abstract.
- Small sample size in the murine model.
- Potential confounding factors not controlled for in the study.